China A roundup of latest news from Chinese pharma and biotech, including a record high share price for Hansoh, strategic healthcare partnerships, venture capital gains, and recent IPO news from Sunshine Guojian and Tigermed. China’s Hansoh Pharma out-licenses cancer drug to U.S. start-up EQRx https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0723/2020072300084.pdf Hansoh Pharmaceutical Group led by…
Cell & Gene Therapy The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s quest for knowledge, costing USD three billion across 13 years. But even after nearly two decades, we have barely scratched…
Boehringer Ingelheim With its brand new hub in Shanghai dedicated to research, business development and venture funding, German pharma giant Boehringer Ingelheim is taking a step further toward accessing innovation from the Chinese biotech industry. Boehringer Ingelheim has its sights set on establishing a deeper rapport with the Chinese biotech sector.…
China Dr Qing Liu, Arctic Vision’s VP for Clinical & Regulatory Affairs, shares her key priorities and the potential for top-line ophthalmological innovations in the Chinese market. Unmet medical needs in eye care are huge in the Asia markets, and biotech companies will become increasingly important players and innovation drivers…
China Dr Yi (York) Chen, VP for operations and commercial planning at Arctic Vision shares his priorities, his wide experience of ophthalmology product launches in China, and how the company is positioning itself in relation to much larger companies in the Chinese ophthalmology market. Fundamentally, we are convinced that the…
China Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the potential to significantly increase success rates in early drug discovery, and the next steps for the company’s expansion. By now, we have a platform of over 500…
Roundup A roundup of the latest from Chinese pharma and biotech, including Boehringer Ingelheim’s new Shanghai R&D hub, new HKEX IPO successes for Chinese firms, further progress for Clover’s COVID-19 vaccine candidate, and more. Boehringer creates Shanghai hub to connect with Chinese R&D groups https://www.fiercebiotech.com/biotech/boehringer-creates-shanghai-hub-to-connect-chinese-r-d-groups With China’s domestic biotech scene…
Brazil In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies that heading into phase III trials. Chinese firm Sinovac recently received regulatory approval to test its vaccine candidate in Brazil…
China The latest news from Chinese pharma, including the latest on Sinopharm’s COVID-19 vaccine, how geopolitical tensions are affecting trade between China and India, and the country’s latest pharma billionaire. China’s Sinopharm touts 100 percent antibody response for COVID-19 vaccine it’s already giving to workers https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving Tuesday, China’s state-run Sinopharm said (Chinese)…
China I recently had the pleasure to moderate an event on the COVID-19 impact on the relationship between Doctor and Patient, attended by 50 executives of the French Healthcare community in China (Club Santé Chine). I would like to share here some learnings and personal thoughts. One of the consequences…
China Chinese biotech CanSinoBIO is racing against the clock to have a COVID-19 vaccine ready to begin production in early 2021. The firm’s senior VP of International Business Pierre Morgon reflects on CanSinoBIO’s progress thus far and a timeline of what we can realistically expect if and when Chinese authorities give…
China Founded by a veteran industry team, Arctic Vision recently celebrated its first anniversary and touts itself as the first innovative ophthalmology-focused biotech in China, with the mission of bringing innovative therapies from abroad to patients in China. According to CEO and cofounder Dr Eddy WU, a company like Arctic…
See our Cookie Privacy Policy Here